FBIO vs XOMA

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -31. 8% for Fortress Biotech, Inc. (FBIO). XOMA Royalty Corp. (XOMA) offers the better valuation at 28. 5x trailing P/E (37. 0x forward), making it the more compelling value choice. Analysts rate Fortress Biotech, Inc. (FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, XOMA Royalty Corp.

is actually cheaper at 37. 0x.

Over the past 5 years, XOMA Royalty Corp.

(XOMA) delivered a total return of +33. 1%, compared to -95. 6% for Fortress Biotech, Inc. (FBIO). Over 10 years, the gap is even starker: XOMA returned +188. 9% versus FBIO's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fortress Biotech, Inc.

(FBIO) is the lower-risk stock at 0. 97β versus XOMA Royalty Corp. 's 1. 21β — meaning XOMA is approximately 24% more volatile than FBIO relative to the S&P 500.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -31. 8% for Fortress Biotech, Inc. (FBIO). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to 68. 2% for Fortress Biotech, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -79. 8% for Fortress Biotech, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus -191. 4% for FBIO. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, XOMA Royalty Corp.

(XOMA) trades at 37. 0x forward P/E versus 255. 0x for Fortress Biotech, Inc. — 218. 0x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Fortress Biotech, Inc. (FBIO) offers the highest yield at 1. 3%, versus 0. 7% for XOMA Royalty Corp. (XOMA).

For long-horizon retirement investors, Fortress Biotech, Inc.

(FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), 1. 3% yield). Both have compounded well over 10 years (FBIO: -94. 3%, XOMA: +188. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FBIO is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.